Innovation Kyoto 2016 Investment Limited Partnership ("KYOTO-icap No.1 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto iCAP") (Head office: Sakyo-ku, Kyoto; Representative Director: Kimi Kusumi) as general partner, has made an investment in Phimex Corporation ("Phimex"), a venture company utilizing Kyoto University's research results. ("Phimex") (Head office: Fujisawa City, Kanagawa Prefecture; Representative Director: Yusuke Tominari), a venture company that utilizes research results from Kyoto University.

Outline of this investment
Phimex is a drug discovery venture company that conducts research and development of novel drugs with proteolytic mechanisms of action. Phimex has acquired a proprietary small molecule that binds to E3 ligase, a component of the ubiquitin-proteasome system, and has developed RaPPIDS™ (Rapid Protein Proteolysis Inducer Discovery System), a drug discovery platform technology to rapidly create proteolysis-inducing agents through proprietary know-how and Diversity Oriented Synthesis. Rapid Protein Proteolysis Inducer Discovery System (RaPPIDS™), a drug discovery platform technology to rapidly create proteolysis inducers through proprietary know-how and Diversity Oriented Synthesis. Based on these technologies, Phimex is advancing several first-in-class development programs targeting proteins related to cancer diseases, which have been considered "undruggable" so far. In addition, Phimex is collaborating with Kyoto University Graduate School of Medicine (Dr. Hyeon-Soo Kim, Associate Professor) to develop new drugs for cancer and infectious diseases. Phimex hopes to use RaPPIDS™ to facilitate future collaborations with leading research institutions and major pharmaceutical companies in Japan and abroad, and to contribute to the provision of new medicines to patients and their families around the world.

Kyoto iCAP highly evaluated the potential of the protease inhibitor developed by Phimex as a new treatment option for patients who have no treatment options, as well as Phimex's policy of contributing to human health through its proprietary platform technology. (Head office: Bunkyo-ku, Tokyo; Representative Director: Katsuhiko Oizumi) and ANRI4 Limited Liability Partnership (Head office: Shibuya-ku, Tokyo; Representative Partner: Yasuri Samata), and subscribed 199,953,600 yen in the Series A round.

Outline of Phimex Corporation

Establishment	January 2018
Business	Drug Discovery based on Targeted Protein Degradation
Head Office Location	Fujisawa City, Kanagawa Prefecture
President & CEO	Yusuke Tominari
Contact	E-mail: info@fimecs.com